VIR - Gates Foundation added LumiraDX pared Atreca stake in Q3

• The main difference in the Bill & Melinda Gates Foundation portfolio in Q3 2022 is the addition of ~14.3M shares of LumiraDx ( NASDAQ: LMDX ), a point-of-care diagnostics company, according to the foundation's 13F filing for Q3 2022.
• In addition, the philanthropic organization that focuses on health issues slightly reduced its holdings in Atreca ( NASDAQ: BCEL ) to 1.32M shares from 1.33M.
• Its other holdings — Amyris ( NASDAQ: AMRS ), BioNTech SE ( NASDAQ: BNTX ), Butterfly Network ( NYSE: BFLY ), CureVac ( NASDAQ: CVAC ), Exscientia ( NASDAQ: EXAI ), Immuncore Holdings Vir Biotechnology ( NASDAQ: VIR ), and Zymergen — remained unchanged during the quarter.
• The Gates Foundation originally disclosed the 7.4% stake in LMDX in July.
• Last month, the foundation committed $1.2B to end polio globally

For further details see: